BACKGROUND: Reliable information on severe morbidity is essential for identifying priorities for case management and to guide resource allocation within the health sector. METHODS: This study describes overall, AIDS- and non-AIDS-related severe morbidity as well as mortality and its determinants in an urban cohort of HIV-infected individuals from a public healthcare institution, the Evandro Chagas Research Institute (IPEC) of the Oswaldo Cruz Foundation, Rio de Janeiro, Brazil. Severe morbid events were defined as all clinical diagnoses listed in hospitalization discharge records; all diagnoses were checked and validated. Generalized estimating equation models were used to estimate incidence rates while adjusting for within-subject correlation. RESULTS: Between 2000 and 2010, 3,537 patients were followed for a total of 16,960 person-years (PY) of follow-up. Over the years, annual incidence rate of severe morbid events, AIDS-related events, non-AIDS-related events, and deaths significantly decreased from, respectively, 36.6, 12.9, 23.7 and 3.2 per 100 PY in 2000 to 25.3, 7.9, 17.4 and 1.9 per 100 PY in 2010. Patients' immunological profiles significantly improved with time; 84% of the patients used combination antiretroviral therapy (cART) per year. Immunodeficiency was associated with a higher incidence rate of AIDS- and non-AIDS-related events as well as with the incidence rate of specific non-AIDS events (bacterial infections, toxicities, cardiovascular, renal and respiratory diseases). CONCLUSIONS: Our results show that in a middle income country with access to cART, non-AIDS-related events represent an important cause of severe morbidity alongside a still high incidence rate of AIDS-related events.
BACKGROUND: Reliable information on severe morbidity is essential for identifying priorities for case management and to guide resource allocation within the health sector. METHODS: This study describes overall, AIDS- and non-AIDS-related severe morbidity as well as mortality and its determinants in an urban cohort of HIV-infected individuals from a public healthcare institution, the Evandro Chagas Research Institute (IPEC) of the Oswaldo Cruz Foundation, Rio de Janeiro, Brazil. Severe morbid events were defined as all clinical diagnoses listed in hospitalization discharge records; all diagnoses were checked and validated. Generalized estimating equation models were used to estimate incidence rates while adjusting for within-subject correlation. RESULTS: Between 2000 and 2010, 3,537 patients were followed for a total of 16,960 person-years (PY) of follow-up. Over the years, annual incidence rate of severe morbid events, AIDS-related events, non-AIDS-related events, and deaths significantly decreased from, respectively, 36.6, 12.9, 23.7 and 3.2 per 100 PY in 2000 to 25.3, 7.9, 17.4 and 1.9 per 100 PY in 2010. Patients' immunological profiles significantly improved with time; 84% of the patients used combination antiretroviral therapy (cART) per year. Immunodeficiency was associated with a higher incidence rate of AIDS- and non-AIDS-related events as well as with the incidence rate of specific non-AIDS events (bacterial infections, toxicities, cardiovascular, renal and respiratory diseases). CONCLUSIONS: Our results show that in a middle income country with access to cART, non-AIDS-related events represent an important cause of severe morbidity alongside a still high incidence rate of AIDS-related events.
Authors: Lara E Coelho; Sayonara R Ribeiro; Andre M Japiassu; Ronaldo I Moreira; Priscila C Lara; Valdilea G Veloso; Beatriz Grinsztejn; Paula M Luz Journal: J Acquir Immune Defic Syndr Date: 2017-08-01 Impact factor: 3.731
Authors: Pedro H A C Leite; Lara E Coelho; Sandra W Cardoso; Ronaldo I Moreira; Valdilea G Veloso; Beatriz Grinsztejn; Paula M Luz Journal: BMC Infect Dis Date: 2022-05-17 Impact factor: 3.667
Authors: Jessica L Castilho; Paula M Luz; Bryan E Shepherd; Megan Turner; Sayonara R Ribeiro; Sally S Bebawy; Juliana S Netto; Catherine C McGowan; Valdiléa G Veloso; Eric A Engels; Timothy R Sterling; Beatriz Grinsztejn Journal: Infect Agent Cancer Date: 2015-02-02 Impact factor: 2.965
Authors: Thiago S Torres; Paula M Luz; Monica Derrico; Luciane Velasque; Eduarda Grinsztejn; Valdiléa G Veloso; Sandra W Cardoso; Marília Santini-Oliveira; Beatriz Grinsztejn; Raquel Brandini De Boni Journal: PLoS One Date: 2014-12-23 Impact factor: 3.240
Authors: Chanelle M Diaz; Eddy R Segura; Paula M Luz; Jesse L Clark; Sayonara R Ribeiro; Raquel De Boni; Leonardo Eksterman; Rodrigo Moreira; Judith S Currier; Valdiléa G Veloso; Beatriz Grinsztejn; Jordan E Lake Journal: BMC Infect Dis Date: 2016-08-08 Impact factor: 3.090
Authors: Lara E Coelho; Sayonara R Ribeiro; Valdilea G Veloso; Beatriz Grinsztejn; Paula M Luz Journal: Braz J Infect Dis Date: 2016-12-03 Impact factor: 1.949
Authors: Juliana Lauar Gonçalves; Maria Clara Amorim Silva; Eric Henrique Roma; Beatriz Grinsztejn; Alberto Dos Santos de Lemos; Nathalia Gorni; Adele Moura Cruz; Cristiane Fonseca de Almeida; Marcel de Souza Borges Quintana; Maria da Gloria Bonecini-Almeida; Patrícia Dias de Brito Journal: Mem Inst Oswaldo Cruz Date: 2020-01-31 Impact factor: 2.743
Authors: Lara E Coelho; Sandra W Cardoso; Rodrigo T Amancio; Ronaldo I Moreira; Sayonara R Ribeiro; Alessandra B Coelho; Dayse P Campos; Valdiléa G Veloso; Beatriz Grinsztejn; Paula M Luz Journal: BMC Infect Dis Date: 2016-03-22 Impact factor: 3.090
Authors: Paula M Luz; Michael P Girouard; Beatriz Grinsztejn; Kenneth A Freedberg; Valdilea G Veloso; Elena Losina; Claudio J Struchiner; Rachel L MacLean; Robert A Parker; A David Paltiel; Rochelle P Walensky Journal: J Int AIDS Soc Date: 2016-03-29 Impact factor: 5.396